BioRestorative Therapies, Inc. (BRTX)

BioRestorative Therapies, Inc. (BRTX) stock has experienced a significant downward trend, declining by 81.74% in the last six months and 85.38% over the past year. In October 2025, the company strengthened its financial position by closing a registered direct offering. In February 2026, BioRestorative Therapies announced the closing of a $5.0 million public offering and completed the enrollment of 99 patients for its Phase 2 clinical trial of BRTX-100. In March 2026, the company reported positive blinded data from its Phase 2 clinical trial for BRTX-100 and achieved alignment with the FDA on key elements for a potential Phase 3 clinical trial.

There is no direct information available to indicate any specific demand seasonality for BioRestorative Therapies, Inc.'s products and services. Demand for its investigational products is likely driven by clinical trial progress, regulatory approvals, and medical need rather than seasonal fluctuations.

BioRestorative Therapies, Inc. is a biotechnology company focused on regenerative medicine using adult stem cells, operating primarily in the Healthcare sector. The company's core business revolves around two clinical development programs, the Disc/Spine Program (brtxDISC™) featuring BRTX-100 for disc disorders, and the Metabolic Program (ThermoStem®) targeting obesity and metabolic disorders. Additionally, they operate a BioCosmeceutical Platform with a commercial biologic serum for aesthetic applications.

BioRestorative Therapies, Inc. is incorporated in Nevada and headquartered in Melville, New York, United States. Clinical trials, such as the Phase 2 trial for BRTX-100, have been conducted across 15 U.S. sites. The company's direct operational geographic footprint appears to be primarily within the United States.

BioRestorative Therapies' brand reputation has been positively impacted by significant advancements in its clinical programs. The company reported encouraging blinded Phase 2 clinical trial results for BRTX-100, demonstrating meaningful improvements in pain and function for patients with chronic lumbar disc disease. Furthermore, the company's alignment with the FDA on key elements for a potential Phase 3 clinical trial for BRTX-100 and its cGMP-compliant, ISO-7 cleanroom cell manufacturing capabilities contribute to its scientific and manufacturing credibility.

The ownership structure of BioRestorative Therapies (BRTX) stock is a mix of institutional, retail, and individual investors. Retail investors hold a significant majority, approximately 97.05% of the stock. Institutional investors hold about 0.53% to 1.23% of the company's stock, while insiders own approximately 1.72%. Lance Alstodt, the CEO, is noted as owning the most shares.